#HUTCHMed
LightNews LightNews
reuters.com
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination reut.rs/3VkeKiC
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination
HUTCHMED (China) said on Tuesday ​that Anglo-Swedish drugmaker AstraZeneca ‌had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO ​combination to treat patients with advanced ​lung cancer.
reut.rs
September 29, 2026 at 5:25 AM
genomeweb.bsky.social
Separately, Hutchmed has begun Phase I testing of an agent that comprises a KRAS inhibitor payload and a anti-EGFR antibody.
AstraZeneca, Hutchmed Eye US Market for EGFR-MET Lung Cancer Combo
AstraZeneca, Hutchmed Eye US Market for EGFR-MET Lung Cancer Combo
ebx.sh
September 30, 2026 at 2:20 AM
2k115.bsky.social
AstraZeneca & HUTCHMED submitted a US NDA for all-oral ORPATHYS + TAGRISSO in EGFRm NSCLC with MET overexpression/amplification post-EGFR-TKI. Phase III SAFFRON trial reported improved survival vs chemotherapy; detailed results follow at ESMO 2026. Filing acceptance pending. #Pharma
AstraZeneca & HUTCHMED: Brief overview of the US FDA New Drug Application for the all-oral ORPATHYS + TAGRISSO combination in MET-driven, EGFR-mutated non-small cell lung cancer.
September 29, 2026 at 7:07 AM
thebiotechtimes.bsky.social
HUTCHMED presenting Phase III data on savolitinib-osimertinib combination for NSCLC at ESMO 2026. Two studies, SAFFRON and SANOVO, both positive. Oral presentations in Madrid this October.
HUTCHMED takes savolitinib-osimertinib combo to ESMO 2026
Two positive Phase III NSCLC studies, SAFFRON and SANOVO, will feature as oral presentations at ESMO Congress 2026 in Madrid this October.
biotech.disruptsmedia.com
September 29, 2026 at 3:00 PM
blueresearch.bsky.social
Hutchmed initiates Phase Ia part of trial of HMPL-A830
Reported Sunday, Sep 27 - 8:41pm EDT (TheFly subscription required to read more.)
thefly.com
September 28, 2026 at 12:50 AM
2k115.bsky.social
AstraZeneca & HUTCHMED submitted a US NDA for all-oral ORPATHYS + TAGRISSO in EGFRm NSCLC with MET overexpression/amplification post-EGFR-TKI. Phase III SAFFRON trial reported improved survival vs chemotherapy; detailed results follow at ESMO 2026. Filing acceptance pending.
September 29, 2026 at 6:52 AM
carpenter22.bsky.social
Hutchmed weighs cancer drug’s supply-chain options amid US-China trade war www.scmp.com/business/art...
Hutchmed weighs cancer drug’s supply-chain options amid trade war
Blood-cancer medicine, manufactured in the US, won conditional approval for sale in mainland China last month.
www.scmp.com
April 14, 2025 at 11:27 AM
biotechstockdaily.bsky.social
HUTCHMED signs a deal worth up to US$1.295B with GSK for experimental cancer therapy HMPL-A830.

#Oncology #Biotech #Cancer #Health

Disclaimer: This is NOT a financial advice
September 8, 2026 at 6:49 AM
fintwitter.bsky.social
HUTCHMED STARTS PHASE III TRIAL OF SURUFATINIB AND CAMRELIZUMAB FOR PANCREATIC CANCER
January 5, 2026 at 12:01 AM
fintwitter.bsky.social
HUTCHMED (CHINA) LTD - NDA ACCEPTANCE IN CHINA FOR FRUQUINTINIB COMBINATION WITH SINTILIMAB
June 4, 2025 at 11:54 PM
fintwitter.bsky.social
HUTCHMED (CHINA) LTD - ACCEPTED FOR REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
June 4, 2025 at 11:54 PM
marketwirenews.com
Just In: ( NASDAQ: #HCM ) HUTCHMED Announces that TAGRISSO plus ORPATHYS demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

#StockMarket #News
October 16, 2024 at 9:20 AM
marketwirenews.com
Breaking News: ( NASDAQ: #HCM ) HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

#StockMarket #News
August 21, 2024 at 9:05 AM
stocktitan.net
#HCM HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

https://www.stocktitan.net/news/HCM/hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-q65kg1tgoq6l.html
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) will present new and updated clinical data at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago). Key results include a pivotal Phase II savolitinib study in MET-amplified gastric/GEJ cancer that met its primary ORR endpoint.The Independent Review Committee–assessed ORR was 32.3% (95% CI: 21.2–45.1), with DCR 63.1%, median TTR 1.4 months, DoR 9.7 months and PFS 4.0 months. These data supported a China NDA that received priority review in December 2025. Multiple fruquintinib and surufatinib studies will also be presented.
www.stocktitan.net
May 22, 2026 at 12:00 AM
fintwitter.bsky.social
HUTCHMED (CHINA) - FRUSICA-2 PHASE II/III STUDY OF FRUQUINTINIB & SINTILIMAB COMBINATION MET PRIMARY ENDPOINT IN CHINA
March 19, 2025 at 12:04 AM
marketwirenews.com
Just In: ( NASDAQ: #HCM ) HUTCHMED Announces Japan Approval for FRUZAQLA (fruquintinib) Received by Takeda

#StockMarket #News
September 24, 2024 at 9:00 AM
fintwitter.bsky.social
Hutchmed completes patient enrollment for Sanovo Phase III trial of Orpathys® + Tagrisso® as first-line therapy for certain lung cancer patients in China.
August 20, 2025 at 12:00 AM
marketwirenews.com
JUST IN: ( NASDAQ: #HCM ) HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda

#StockMarket #News
October 31, 2024 at 10:35 AM
ipharmaservices.bsky.social
Breakthrough: NMPA grants conditional approval to Orpathys for MET-amplified gastric cancer in China, offering new hope for patients. www.ipharmacenter.com/post/orpathy... #news #pharma #healthcare #oncology #gastriccancer #biotech
Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter
HUTCHMED has secured conditional approval from China’s National Medical Products Administration for savolitinib, marketed as Orpathys, in a new gastric cancer indication.The decision allows oncologist...
www.ipharmacenter.com
July 11, 2026 at 6:38 AM
ipharmaservices.bsky.social
Avanço na #oncologia: A NMPA concede aprovação condicional ao Orpathys para câncer gástrico com amplificação MET na #China. www.ipharmacenter.com/post/orpathy... #notícias #farmacêutica #saúde #oncologia #cancergastrico
Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter
HUTCHMED has secured conditional approval from China’s National Medical Products Administration for savolitinib, marketed as Orpathys, in a new gastric cancer indication.The decision allows oncologist...
www.ipharmacenter.com
July 11, 2026 at 6:42 AM
blueresearch.bsky.social
Hutchmed price target raised by $2 at BofA
Reported Monday, Sep 21 - 6:39am EDT (TheFly subscription required to read more.)
thefly.com
September 21, 2026 at 10:40 AM
ipharmaservices.bsky.social
#ESMOGI26 - Fanregratinib montre un signal robuste en phase II dans le CCI lié à FGFR2 ipharmacenter.com/post/esmo-ga... #pharma #Oncologie #Oncotwitter #OncoAlert #Cancer #innovation #HUTCHMed #actualités #dernièreminute #news #breakingnews
ESMO Gastrointestinal Cancers Congress 2026 | iPharmaCenter
Fanregratinib Delivers Strong Phase II Signal in FGFR2‑Driven iCCAHUTCHMED tested its FGFR inhibitor fanregratinib (HMPL‑453) in a registration‑oriented Phase II study run at 53 hospitals across China...
ipharmacenter.com
June 29, 2026 at 10:57 AM
ipharmaservices.bsky.social
HUTCHMED’s Orpathys (savolitinib) receives conditional NMPA approval in China for MET-amplified gastric & GEJ adenocarcinoma.
www.ipharmacenter.com/post/orpathy...
#news #media #pharma #pharmaceutical #healthcare #globalhealth #healthforall #OncoTwitter #ASCO26
Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter
HUTCHMED has secured conditional approval from China’s National Medical Products Administration for savolitinib, marketed as Orpathys, in a new gastric cancer indication.The decision allows oncologist...
www.ipharmacenter.com
July 8, 2026 at 1:58 PM
ipharmaservices.bsky.social
Hito en oncología: La NMPA otorga aprobación condicional a Orpathys para el cáncer gástrico con amplificación MET en China. www.ipharmacenter.com/post/orpathy... #noticias #farmacia #salud #oncologia #cancergastrico
Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter
HUTCHMED has secured conditional approval from China’s National Medical Products Administration for savolitinib, marketed as Orpathys, in a new gastric cancer indication.The decision allows oncologist...
www.ipharmacenter.com
July 11, 2026 at 6:39 AM
ipharmaservices.bsky.social
Avancée majeure : l'administration chinoise (NMPA) approuve Orpathys sous condition pour le traitement du cancer gastrique avec amplification MET. www.ipharmacenter.com/post/orpathy... #actualités #pharma #santé #oncologie #cancer
Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter
HUTCHMED has secured conditional approval from China’s National Medical Products Administration for savolitinib, marketed as Orpathys, in a new gastric cancer indication.The decision allows oncologist...
www.ipharmacenter.com
July 11, 2026 at 6:39 AM